Skip to main content
. 2019 Dec 11;9(12):e031019. doi: 10.1136/bmjopen-2019-031019

Figure 2.

Figure 2

Tornado diagrams. The graphic shows the impact of varying individual model inputs on the cost-effectiveness of pembrolizumab plus chemotherapy for metastatic NSCLC. ICER, incremental cost-effectiveness ratio; nSCLC, non-small cell lung cancer.